Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

This descriptive, retrospective observational study used the Japan Medical Data Vision Co., Ltd. (MDV), database (June 2017–November 2018) and covered data for EGFR, ALK, ROS1, and PD-L1; records on BRAF testing were not yet available. This real-world evidence revealed variations in diagnostic testing patterns, which could affect time to treatment in Japan. Variations are likely influenced by individual biomarker prioritization considering limited tissue samples in clinical practice. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/j.jtocrr.2020.100136

Authors: Yasushi Yatabe, Yasumasa Yoshiki, MPH, Koichi Matsumura, Kanae Togo, MSc, Hironori Kikkawa, Laura Iadeluca, MPH, Benjamin Li, Kazuto Nishio,

Real-World OutcomesKirk SmithDecember 29, 2020Lung cancer, Companion diagnostics, Biomarker testing, Time to treatment, Real-world data in Japan